- Home
- PLX vs JHS Comparison
PLX vs JHS Comparison
Compare PLX & JHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- JHS
- Stock Information
- Founded
- PLX 1993
- JHS 1973
- Country
- PLX United States
- JHS United States
- Employees
- PLX N/A
- JHS N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- JHS Finance Companies
- Sector
- PLX Health Care
- JHS Finance
- Exchange
- PLX Nasdaq
- JHS Nasdaq
- Market Cap
- PLX 127.4M
- JHS 131.4M
- IPO Year
- PLX 1998
- JHS N/A
- Fundamental
- Price
- PLX $1.55
- JHS $11.56
- Analyst Decision
- PLX Strong Buy
- JHS
- Analyst Count
- PLX 1
- JHS 0
- Target Price
- PLX $15.00
- JHS N/A
- AVG Volume (30 Days)
- PLX 571.5K
- JHS 32.8K
- Earning Date
- PLX 08-14-2025
- JHS 01-01-0001
- Dividend Yield
- PLX N/A
- JHS 3.96%
- EPS Growth
- PLX N/A
- JHS N/A
- EPS
- PLX 0.08
- JHS 0.02
- Revenue
- PLX $61,948,000.00
- JHS N/A
- Revenue This Year
- PLX $14.53
- JHS N/A
- Revenue Next Year
- PLX $75.77
- JHS N/A
- P/E Ratio
- PLX $20.34
- JHS $553.50
- Revenue Growth
- PLX 62.79
- JHS N/A
- 52 Week Low
- PLX $0.89
- JHS $9.76
- 52 Week High
- PLX $3.10
- JHS $11.25
- Technical
- Relative Strength Index (RSI)
- PLX 47.97
- JHS 60.60
- Support Level
- PLX $1.47
- JHS $11.49
- Resistance Level
- PLX $1.57
- JHS $11.60
- Average True Range (ATR)
- PLX 0.07
- JHS 0.10
- MACD
- PLX -0.00
- JHS -0.00
- Stochastic Oscillator
- PLX 31.82
- JHS 65.63
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About JHS John Hancock Income Securities Trust
John Hancock Income Securities Trust is a United States-based closed-ended diversified management investment company. Its primary objective is to generate a high level of current income consistent with prudent investment risk. The fund invests its net assets (plus borrowings for investment purposes) in income securities, consisting of marketable corporate debt securities, governmental obligations, and cash and commercial paper. A majority of its net assets are invested in debt securities that are rated, at the time of acquisition, investment-grade or in unrated securities determined by the Fund's investment advisor or subadvisor to be of comparable credit quality.